<DOC>
	<DOCNO>NCT03105102</DOCNO>
	<brief_summary>The study consist 3 sub-studies , follow : - Sub-study 1 ( Randomized , double-blind , placebo control study ) evaluate efficacy safety risankizumab versus placebo maintenance therapy subject moderately severely active Crohn 's disease ( CD ) respond risankizumab induction treatment Study M16-006 Study M15-991 - Sub-study 2 ( Randomized , exploratory maintenance study ) evaluate efficacy safety two different dose regimen risankizumab maintenance therapy subject respond induction treatment Study M16-006 Study M15-991 ; - Sub-study 3 ( Open-label , long-term extension study ) evaluate long-term safety risankizumab subject complete Sub-study 1 2 .</brief_summary>
	<brief_title>A Study Efficacy Safety Risankizumab Subjects With Crohn 's Disease Who Responded Induction Treatment M16-006 M15-991</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects complete Study M16006 Study M15991 achieve clinical response Subject consider Investigator , reason , unsuitable candidate study Subject know hypersensitivity risankizumab excipients study drug ingredient CHO , AE Studies M16 006 M15991 Investigator 's judgment make subject unsuitable study Subject compliance prior concomitant medication requirement throughout Studies M16006 M15991</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>ABBV-066</keyword>
	<keyword>risankizumab</keyword>
	<keyword>BI 655066</keyword>
</DOC>